IMP 4297

Drug Profile

IMP 4297

Alternative Names: IMP 4297; IMPO4297

Latest Information Update: 08 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IMPACT Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 May 2017 Phase-I clinical trials in Solid tumours in China (PO) prior to May 2017
  • 10 Apr 2017 IMPACT Therapeutics plans a phase Ib trial in Australia/China for Solid tumours
  • 30 Mar 2017 IMPACT Therapeutics plans a phase II/III trial in Breast, ovarian, or prostate cancer (IMPACT Therapeutics website, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top